The present invention relates to novel hydroxyethylamine compounds having Asp2 (.beta.-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated .beta.-amyloid levels or .beta.-amyloid deposits, particularly Alzheimer's disease.